Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
X4 Pharmaceuticals, Inc (XFOR)
A forensic read on X4 Pharmaceuticals, Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-1.5
Altman Z-score
Watch
Earnings quality
4
Forensic signals
-94.9%
ROE
$379M
Market cap
X4 Pharmaceuticals, Inc earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -1.5, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-144%Return on invested capital.Return on invested capital is -144% and rising from -538% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
stoppedShareholder returns — halted.Capital returns have STOPPED — $2M of buybacks + dividends in FY2021, but ~$0 in FY2023. A halt usually means the company is conserving cash; understand why before reading it as neutral.
66% of revStock-based comp load.Stock-based compensation ran 66% of revenue in FY2025 — about $0.10 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
$10MGoodwill impairments.Took $10M of goodwill writedowns across 1 year(s) (FY2021 ($10M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-1218.4%
Debt / Equity0.40x
Free Cash Flow$-85.6M
Latest Revenue$6.5M
Return on Equity-42.5%
Revenue Growth YoY+150.0%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on X4 Pharmaceuticals, Inc:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about XFOR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown